Recommended

Lilly demonstrates alopecia areata promise in major study
Novartis bets $12bn on potential first-in-class RNA therapeutics
Process analytical tool could aid real-time monitoring in vaccine manufacturing
CPHI Pharma Awards 2025 winners announced
Drug delivery study offers potential “paradigm shift” in restenosis
Lilly AI supercomputer set to advance pharma manufacturing
FDA draft guidance to streamline biosimilar development
Novo Nordisk bids $6.5 billion for Metsera
news

Jonathan Brüün to leave CEO role at the British Pharmacological Society

0
SHARES

Brüün has announced he will be leaving his role as CEO at the BPS and moving to a new role at the Royal College of Anaesthetists.

Jonathan Brüün (credit: British Pharmacological Society, www.bps.ac.uk).

Jonathan Brüün has announced he will be leaving his role as CEO of the British Pharmacological Society (BPS) in January 2020. He will be taking up a new post as Chief Executive of the Royal College of Anaesthetists.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Brüün became CEO of the British Pharmacological Society in June 2012. He has had overall responsibility for strategic and financial management, business development, human resources, policy development, governance and the oversight of projects that are designed to support the UK and international pharmacology community.

During Brüün’s time as CEO, the British Pharmacological Society membership rose by over 20 percent. He also expanded the staff team in this same period to ensure effective delivery of the Society’s core objectives – the promotion of the discipline of pharmacology, clinical pharmacology and therapeutics.

“I’m very proud of everything we have achieved together, whether it’s the growth in member numbers and satisfaction, the establishment of a policy unit which truly punches above its weight, the focus on quality in our annual meetings and the development of a content strategy led by a scientific advisory panel to help deliver this, the continued professionalisation of the BPS office and the generation of new sources of revenue to underpin our future activities. All this will ensure BPS will be a happy and inclusive home for anyone with an interest in pharmacology, clinical pharmacology and therapeutics in future,” said Brüün.

The Trustees of the Society will meet 22 August 2019 to plan the recruitment process for a new CEO, which is expected to begin imminently.

Share via
Share via